Urgent

Critical congenital heart disease (CCHD) pulse-oximetry screening in the newborn

Newborn pulse-oximetry screening · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Pulse-oximetry screening detects critical (often duct-dependent) congenital heart disease that can be missed on antenatal scan and clinical examination, by identifying hypoxaemia before collapse. Screening is performed on apparently well newborns, typically after 24 hours (or before discharge), using pre- and post-ductal saturations.

Red flags

  • Any SpO2 below 90%
  • Weak or absent femoral pulses
  • Signs of shock or collapse
  • Marked pre-/post-ductal differential suggesting duct-dependent systemic or pulmonary flow
  • Cyanosis unresponsive to oxygen

Assessment

Differential diagnosis

  • Critical/duct-dependent congenital heart disease
  • Persistent pulmonary hypertension of the newborn
  • Sepsis/pneumonia
  • Respiratory distress (RDS/TTN/MAS)
  • Non-cardiac causes of low SpO2 (e.g. methaemoglobinaemia)
  • Normal transition / probe artefact (false positive)

Investigations

  • Pre-ductal (right hand) and post-ductal (either foot) SpO2 with a motion-tolerant oximeter
  • Full clinical examination including femoral pulses and four-limb BP if abnormal
  • Chest radiograph and ECG when screen positive
  • Echocardiography for a positive screen or clinical concern
  • Blood gas, glucose and sepsis screen as indicated

Management

  • Perform screening on well babies ideally at 24–48 hours of age (or before earlier discharge), avoiding crying/cold states.
  • Measure SpO2 in the right hand (pre-ductal) and one foot (post-ductal) with a neonatal probe.
  • Interpret as a POSITIVE screen if any SpO2 <90%; this needs immediate assessment.
  • Interpret as a POSITIVE screen if SpO2 is 90–94% in both limbs, OR a pre-/post-ductal difference >3%, on repeated measurement.
  • Repeat borderline readings (90–94% or >3% difference) at intervals (e.g. up to two further checks about an hour apart) before confirming positive.
  • Interpret as PASS if SpO2 ≥95% in either limb AND the pre-/post-ductal difference is ≤3%.
  • For any SpO2 <90% or a persistently positive screen, perform urgent clinical review and arrange echocardiography.
  • While awaiting diagnosis in a collapsing or clearly cyanotic infant, consider prostaglandin for a suspected duct-dependent lesion.
  • Exclude and treat non-cardiac causes (sepsis, lung disease, PPHN) in parallel.
  • Do not discharge a baby with an unexplained positive screen.
  • Document results clearly and counsel parents.
  • Remember screening does not detect all CHD – maintain clinical vigilance after a pass.

Drugs & doses

Prostaglandin E1 (alprostadil) 5–20 nanogram/kg/min IV to maintain ductal patency in suspected duct-dependent CHD
Oxygen titrated to clinical need (avoid high FiO2 masking duct-dependent lesions)
0.9% sodium chloride 10 mL/kg IV for shock while awaiting diagnosis
Benzylpenicillin 50 mg/kg IV plus gentamicin 5 mg/kg IV if sepsis cannot be excluded

Disposition

Postnatal/transitional care with oximetry; positive screen prompts urgent paediatric/neonatal review and echocardiography; transfer to a cardiac centre if duct-dependent CHD is confirmed.

Complications & pitfalls

  • Delayed diagnosis leading to cardiovascular collapse
  • False-positive screens causing parental anxiety and over-investigation
  • Missed CHD that is not hypoxaemic at screening
  • Hypoxic end-organ injury
  • Apnoea from prostaglandin if started empirically

Exam pearls

  • Screen after 24 hours where possible to reduce false positives from normal transition.
  • A pre-/post-ductal gradient >3% is significant even if absolute saturations look acceptable.
  • A normal screen does not exclude all CHD (e.g. coarctation can pass).
  • Prostaglandin can be life-saving while the diagnosis is confirmed – but watch for apnoea.
  • Interpret saturations alongside femoral pulses and the full clinical picture.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.